Lymphoma treatment response monitoring with genetic testing

This study checks whether measuring a blood test called “circulating tumor DNA” (ctDNA) helps monitor childhood lymphoma during treatment. It’s meant to see if ctDNA tracking can provide useful information alongside standard exams.

This trial looks at your tumor’s genetic information from stored tissue to help match you to early-phase treatment options. It may help doctors find a therapy that fits your tumor, especially when standard options have limited benefit.

This trial studies whether using a blood test (ctDNA) can help guide treatment decisions for people with newly diagnosed diffuse large B-cell lymphoma. It tests standard chemotherapy regimens (R-CHOP or R-pola-CHP) and aims to improve outcomes by monitoring tumor DNA in the blood.

This study uses a blood test to detect cancer DNA (ctDNA) in children and young adults with classical Hodgkin lymphoma. The goal is to see if this non-invasive test can help track how well treatment is working.

This study looks at a blood test called circulating tumor DNA, measured after 6 months of treatment, to see how well it predicts outcomes in people with Waldenström macroglobulinemia. It may help doctors better judge who is responding and who may need treatment adjustments earlier.

This study follows patients with aggressive B-cell lymphoma during treatment using advanced blood tests (ctDNA) and PET imaging to detect how well the cancer is responding. The goal is to find better ways to monitor treatment in real time.